COMMUNIQUÉS West-GlobeNewswire
-
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
17/08/2026 -
Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options
17/08/2026 -
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
17/08/2026 -
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
17/08/2026 -
Novo Nordisk A/S - share repurchase programme
17/08/2026 -
INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
17/08/2026 -
Ever After Foods Acquires Fishway to Expand Integrated Food Production Technology Platform
17/08/2026 -
TOMI Secures Critical Ireland Market Approval, Strengthening SteraMist's Position Across the European Union
17/08/2026 -
Clene to Present at the Emerging Growth Conference
17/08/2026 -
Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director
17/08/2026 -
Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure
17/08/2026 -
NewGenIVF Completes Exchange of Convertible Notes with Institutional Investor
17/08/2026 -
Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’
17/08/2026 -
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
17/08/2026 -
Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification
17/08/2026 -
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
17/08/2026 -
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
17/08/2026 -
AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
17/08/2026 -
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026
17/08/2026
Pages